Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Alzheimer’s disease
Biomarkers
CSF
Memory clinic
p-tau181
p-tau217
p-tau231
p-tau235
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
10 03 2023
10 03 2023
Historique:
received:
07
12
2022
accepted:
28
02
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer's disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ -). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ- groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A-T- and A+T- groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings.
Sections du résumé
BACKGROUND
Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer's disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231.
METHODS
CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ -). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ
RESULTS
High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ- groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A-T- and A+T- groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts.
CONCLUSIONS
CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings.
Identifiants
pubmed: 36899441
doi: 10.1186/s13195-023-01201-0
pii: 10.1186/s13195-023-01201-0
pmc: PMC9999575
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
tau Proteins
0
MAPT protein, human
0
Types de publication
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
48Subventions
Organisme : NIA NIH HHS
ID : R01 AG068398
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Front Aging Neurosci. 2021 Feb 12;13:631770
pubmed: 33643025
Alzheimers Res Ther. 2019 Nov 23;11(1):91
pubmed: 31759396
Sci Rep. 2020 Nov 18;10(1):20058
pubmed: 33208795
EMBO Mol Med. 2021 Dec 7;13(12):e15098
pubmed: 34725927
Alzheimers Dement. 2020 Apr;16(4):589-597
pubmed: 32067357
Alzheimers Dement. 2022 Nov 12;:
pubmed: 36370462
Nat Med. 2022 Dec;28(12):2555-2562
pubmed: 36456833
J Biol Chem. 1992 Aug 25;267(24):17047-54
pubmed: 1512244
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Arch Biochem Biophys. 1998 Sep 15;357(2):299-309
pubmed: 9735171
Acta Neuropathol. 2021 May;141(5):709-724
pubmed: 33585983
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Neurologia (Engl Ed). 2022 Aug 9;:
pubmed: 35961506
Neurology. 2021 Aug 2;:
pubmed: 34341151
Alzheimers Dement. 2021 May;17(5):755-767
pubmed: 33252199
J Neurochem. 2004 Jan;88(2):349-58
pubmed: 14690523
Acta Neuropathol. 2018 Dec;136(6):821-853
pubmed: 30488277
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Brain. 2022 Aug 27;145(8):2834-2848
pubmed: 35311972
Mol Cell Neurosci. 2019 Jun;97:18-33
pubmed: 30529601
J Biol Chem. 2007 Aug 10;282(32):23645-54
pubmed: 17562708
Biochemistry. 1997 Jul 1;36(26):8114-24
pubmed: 9201960
Nat Commun. 2020 Apr 3;11(1):1683
pubmed: 32246036
Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97
pubmed: 11831556
Alzheimers Dement. 2022 Apr;18(4):602-611
pubmed: 34310832
Biochem Biophys Res Commun. 2006 Aug 4;346(3):819-28
pubmed: 16781671
J Alzheimers Dis. 2014;38(2):319-29
pubmed: 23963290
Lancet Neurol. 2020 May;19(5):422-433
pubmed: 32333900
Biomark Med. 2018 Jul;12(7):799-812
pubmed: 29902934
EBioMedicine. 2022 Feb;76:103836
pubmed: 35158308
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Front Aging Neurosci. 2019 May 21;11:121
pubmed: 31178717
Lancet Neurol. 2020 Mar;19(3):271-278
pubmed: 31958406
Neurology. 2002 Jun 25;58(12):1791-800
pubmed: 12084879